19.09.2014 - In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.
In future, Bayer intends to only do business in the fields of human, animal and plant health. To achieve this, the Leverkusen-based company intends to float the material science business on the stock market as a separate company by 2016. The life sciences already account for about 70% of Bayer’s sales, and over the last few years the material science business has been pushed more and more into the background.
The company’s management board is now repositioning itself accordingly. “Our intention is to create two top global corporations: Bayer as a world-class innovation company in the Life Science businesses, and MaterialScience as a leading player in polymers,” CEO Marijn Dekkers announced. He said both companies have excellent prospects for success in their respective industries. “Bayer will continue as an enterprise with an attractive and balanced portfolio and a primary focus on organic growth,” Dekkers explained. To this end, the company intends to raise its R&D spending and selectively strengthen early research at the interface between Healthcare and CropScience. Bayer also wants to continue driving the successful commercialisation of the newly launched pharmaceutical products, such as anticoagulant Xarelto, eye medicine Eylea and cancer drug Xofigo. From these pharmaceutical products, Bayer expects to make combined peak annual sales of at least €7.5bn.
15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.
12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.
09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.